Outcome of Colorectal Cancer Patients Treated with Combination Bevacizumab Therapy: A Pooled Retrospective Analysis of Three European Cohorts from the Angiopredict Initiative

Johannes Betge,Ana Barat,Verena Murphy,Thomas Hielscher,Nicole C.T. van Grieken,Sebastian Belle,Tianzuo Zhan,Nicolai Härtel,Melanie Kripp,Orna Bacon,Martijn Cordes,Elaine Kay,Henk M.W. Verheul,Maarten Neerincx,Bryan T. Hennessy,Ralf Hofheinz,Timo Gaiser,Bauke Ylstra,Jochen H. M. Prehn,Diether Lambrechts,Annette T. Byrne,Matthias P.A. Ebert,Nadine Schulte

Outcome of Colorectal Cancer Patients Treated with Combination Bevacizumab Therapy: A Pooled Retrospective Analysis of Three European Cohorts from the Angiopredict Initiative

2016

Background/Aims: This study is aimed at analyzing the survival rates and prognostic factors of stage IV colorectal cancer patients from 3 European cohorts undergo

Keywords:

Bevacizumab
Stage IV Colorectal Cancer
Colorectal cancer
Diabetes mellitus
Medicine
Oncology
Internal medicine
combination chemotherapy
overall survival
tumor grade
Observed Survival
retrospective analysis
Chemotherapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations